Zymeworks, GSK enter antibody deal

Zymeworks Inc. (Vancouver, B.C.) and GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) entered a collaboration to develop and commercialize mAbs and bispecific antibodies with optimized Fc domains using Zymeworks' Effector Function Enhancement and Control Technology (EFECT) platform.

Both companies will have rights to candidates under the partnership. GSK will receive rights to develop a minimum of four candidates across multiple disease areas. Zymeworks will be eligible for $110 million in milestones per candidate, plus tiered royalties. Zymeworks and GSK declined to disclose further financial terms. ...